IP Library › Granted Patent US 10,336,743
Granted Patent B2
US 10,336,743 · App. 15/374,013 · Granted Jul 2, 2019

Aminopyrimidine kinase inhibitors

Inventors: Carmen M. Baldino (Woburn, MA); Justin L. Caserta (Billerica, MA); Chee-Seng Lee (Somerville, MA); Stephane A. Dumas (Cambridge, MA); Yvonne L. Flanders (Medford, MA)
Assignee: Jasco Pharmaceuticals, LLC
C07D417/14A61K31/506A61K31/519A61K31/5377A61K31/675C07D417/06C07D487/04C07F9/65583C07F9/65586
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,336,743
App. No.
15/374,013
Granted
Jul 2, 2019
Kind
B2
Abstract

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK1γ1, CK1γ2, CK1γ3, CK2, Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK1γ1, CK1γ2, CK1γ3, CK2, Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway.

Claims (21)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is selected from the group consisting of:

3. The compound of claim 1 , wherein the compound is selected from the group consisting of:

4. The compound of claim 1 , wherein the compound is selected from the group consisting of

5. The compound of claim 1 , wherein the compound is selected from the group consisting of

6. The compound of claim 1 , wherein the compound is selected from the group consisting of

7. The compound of claim 1 , wherein the compound is

8. The compound of claim 1 , wherein the compound is

9. The compound of claim 1 , wherein the compound is

10. The compound of claim 1 , wherein the compound is

11. The compound of claim 1 , wherein the compound is

12. The compound of claim 1 , wherein the compound is

13. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier; and a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

14. The pharmaceutical composition of claim 13 , wherein the compound is

15. The pharmaceutical composition of claim 13 , wherein the compound is

16. The pharmaceutical composition of claim 13 , wherein the compound is

17. The pharmaceutical composition of claim 13 , wherein the compound is

18. The pharmaceutical composition of claim 13 , wherein the compound is

19. The pharmaceutical composition of claim 13 , wherein the compound is

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2024
From: JASCO PHARMACEUTICALS, LLC
To: P2K DYNAMICS INC.
Reel/Frame 067725/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2016
From: BALDINO, CARMEN M.; CASERTA, JUSTIN L.; DUMAS, STEPHANE A.; FLANDERS, YVONNE L.; LEE, CHEE-SENG
To: JASCO PHARMACEUTICALS, LLC
Reel/Frame 040874/0991 →
Continuity (4)
Continuation 14577079 · Dec 19, 2014
Continuation 13659343 · Oct 24, 2012
Provisional Application 61555617 · Nov 4, 2011
Related Publication 20170247367A1 · Aug 31, 2017